Program Description
Non-small cell lung cancer (NSCLC)
accounts for approximately 85% of all lung cancer diagnoses and remains a
leading cause of cancer-related mortality worldwide. Increasing recognition of
oncogenic drivers, including HER2 mutations, amplifications, and overexpression,
has expanded the therapeutic landscape, but despite recent advances in
molecularly targeted therapies, new diagnostic and management complexities also
have been introduced. These distinct HER2 alterations require accurate detection
through advanced biomarker testing technologies, which are areas where oncology
pharmacists play a pivotal clinical role. As novel HER2-directed therapies,
including tyrosine kinase inhibitors, monoclonal antibodies, and antibody-drug
conjugates, enter the treatment landscape, pharmacists must navigate evolving
data, resistance mechanisms, and toxicity profiles to ensure the delivery of
patient-centered, evidence-based care. In this case-driven panel discussion,
experts will explore real-world scenarios, discuss emerging evidence, and
challenge participants to apply clinical reasoning through opportunities for
interactive polling and audience response to topics such as biomarker
interpretation, therapy optimization, and toxicity management to improve
outcomes for patients with HER2-altered NSCLC.
Target audience: Oncology Pharmacist
Type of activity: Application
Release date: April 28, 2026
Expiration date: April 28, 2027
Learner level: Advanced
Time to complete activity: 1.5 hour
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Differentiate among HER2 mutations, amplifications, and protein overexpression in non-small cell lung cancer (NSCLC) based on molecular profiles, clinical implications, and diagnostic approaches
- Identify appropriate HER2-targeted therapy for patients with NSCLC by considering biomarker status, clinical characteristics, current evidence, and guideline recommendations
- Employ pharmacist-driven monitoring, patient education, and dose-modification strategies to effectively manage toxicities associated with HER2-targeted treatments in NSCLC
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here